Discovery of a new class of potent MMP inhibitors by structure-based optimization of the arylsulfonamide scaffold

ACS Medicinal Chemistry Letters

Volumn 4, Issue 6, 2013, Pages 565-569

  Mori, Mattia ^a,c   Massaro, Assunta ^a   Calderone, Vito ^a   Fragai, Marco ^a   Luchinat, Claudio ^a   Mordini, Alessandro ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ICCOM CNR   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Desolvation; Docking; Free energy; MMP; Synthesis; X ray

Indexed keywords

CARBOXYLIC ACID; COLLAGENASE 3; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE;

ARTICLE; CHEMICAL STRUCTURE; HYDROGEN BOND; LIGAND BINDING; PRIORITY JOURNAL; QUANTUM MECHANICS; SOLVATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

EID: 84879110483     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300446a     Document Type: Article

References (31)

1. Baramova, E.; Foidart, J. M. Matrix metalloproteinase family. Cell Biol. Int. 1995, 19 (3), 239-42.
2. Vincenti, M. P. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol. Biol. 2001, 151, 121-48.
3. Mori, M.; De Lorenzo, E.; Torre, E.; Fragai, M.; Nativi, C.; Luchinat, C.; Arcangeli, A. A highly soluble matrix metalloproteinase-9 inhibitor for potential treatment of dry eye syndrome. Basic Clin. Pharmacol. Toxicol. 2012, 111 (5), 289-95.
4. Mori, M.; Manetti, F.; Botta, M. Predicting the binding mode of known NCp7 inhibitors to facilitate the design of novel modulators. J. Chem. Inf. Model. 2011, 51 (2), 446-54.
5. Devel, L.; Beau, F.; Amoura, M.; Vera, L.; Cassar-Lajeunesse, E.; Garcia, S.; Czarny, B.; Stura, E. A.; Dive, V. Simple pseudo-dipeptides with a P2′ glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins. J. Biol. Chem. 2012, 287 (32), 26647-56.
6. Devel, L.; Rogakos, V.; David, A.; Makaritis, A.; Beau, F.; Cuniasse, P.; Yiotakis, A.; Dive, V. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J. Biol. Chem. 2006, 281 (16), 11152-60.
7. Li, W.; Li, J.; Wu, Y.; Rancati, F.; Vallese, S.; Raveglia, L.; Wu, J.; Hotchandani, R.; Fuller, N.; Cunningham, K.; Morgan, P.; Fish, S.; Krykbaev, R.; Xu, X.; Tam, S.; Goldman, S. J.; Abraham, W.; Williams, C.; Sypek, J.; Mansour, T. S. Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma. J. Med. Chem. 2009, 52 (17), 5408-19.
8. Li, W.; Li, J.; Wu, Y.; Wu, J.; Hotchandani, R.; Cunningham, K.; McFadyen, I.; Bard, J.; Morgan, P.; Schlerman, F.; Xu, X.; Tam, S.; Goldman, S. J.; Williams, C.; Sypek, J.; Mansour, T. S. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3- sulfonamido)-3-methylbutanoic acid (MMP408). J. Med. Chem. 2009, 52 (7), 1799-802.
9. Rubino, M. T.; Agamennone, M.; Campestre, C.; Campiglia, P.; Cremasco, V.; Faccio, R.; Laghezza, A.; Loiodice, F.; Maggi, D.; Panza, E.; Rossello, A.; Tortorella, P. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem 2011, 6 (7), 1258-68.
10. Wu, Y.; Li, J.; Wu, J.; Morgan, P.; Xu, X.; Rancati, F.; Vallese, S.; Raveglia, L.; Hotchandani, R.; Fuller, N.; Bard, J.; Cunningham, K.; Fish, S.; Krykbaev, R.; Tam, S.; Goldman, S. J.; Williams, C.; Mansour, T. S.; Saiah, E.; Sypek, J.; Li, W. Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorg. Med. Chem. Lett. 2012, 22 (1), 138-43.
11. Bertini, I.; Calderone, V.; Cosenza, M.; Fragai, M.; Lee, Y. M.; Luchinat, C.; Mangani, S.; Terni, B.; Turano, P. Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (15), 5334-9.
12. Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Mangani, S.; Terni, B. Crystal structure of the catalytic domain of human matrix metalloproteinase 10. J. Mol. Biol. 2004, 336 (3), 707-16.
13. Moy, F. J.; Chanda, P. K.; Chen, J.; Cosmi, S.; Edris, W.; Levin, J. I.; Rush, T. S.; Wilhelm, J.; Powers, R. Impact of mobility on structure-based drug design for the MMPs. J. Am. Chem. Soc. 2002, 124 (43), 12658-12659.
14. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug Discovery Today 2003, 8 (19), 876-7.
15. Bertini, I.; Calderone, V.; Fragai, M.; Giachetti, A.; Loconte, M.; Luchinat, C.; Maletta, M.; Nativi, C.; Yeo, K. J. Exploring the subtleties of drug-receptor interactions: The case of matrix metalloproteinases. J. Am. Chem. Soc. 2007, 129 (9), 2466-2475.
16. Attia, M. I.; Timmermann, M.; Hogger, P.; Herdeis, C. Design, synthesis and biological activity of azasugar-based CD163 ectodomain shedding inhibitors. Eur. J. Org. Chem. 2007, 22, 3669-3675.
17. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2009, 30 (16), 2785-2791.
18. Iranpoor, N.; Firouzabadi, H.; Aghapour, G.; Vaezzadeh, A. R. Triphenylphosphine/2,3-dichloro-5,6-dicyanobenzoquinone as a new, selective and neutral system for the facile conversion of alcohols, thiols and selenols to alkyl halides in the presence of halide ions. Tetrahedron 2002, 58 (43), 8689-8693.
19. Matter, H.; Schudok, M.; Schwab, W.; Thorwart, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Weithmann, K. U.; Wollmann, T. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: Design, synthesis and structure-activity relationship. Bioorg. Med. Chem. 2002, 10 (11), 3529-3544.
20. Massaro, A.; Mordini, A.; Reginato, G.; Russo, F.; Taddei, M. Microwave-assisted transformation of esters into hydroxamic acids. Synthesis 2007, 20, 3201-3204.
21. Attolino, E.; Calderone, V.; Dragoni, E.; Fragai, M.; Richichi, B.; Luchinat, C.; Nativi, C. Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs). Eur. J. Med. Chem. 2010, 45 (12), 5919-5925.
22. Devel, L.; Garcia, S.; Czarny, B.; Beau, F.; LaJeunesse, E.; Vera, L.; Georgiadis, D.; Stura, E.; Dive, V. Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1′ loop canonical conformation. J. Biol. Chem. 2010, 285 (46), 35900-9.
23. Subramaniam, R.; Haldar, M. K.; Tobwala, S.; Ganguly, B.; Srivastava, D. K.; Mallik, S. Novel bis-(arylsulfonamide) hydroxamatebased selective MMP inhibitors. Bioorg. Med. Chem. Lett. 2008, 18 (11), 3333-7.
24. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 2005, 12 (2), 181-9.
25. Devel, L.; Czarny, B.; Beau, F.; Georgiadis, D.; Stura, E.; Dive, V. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1′ cavity. Biochimie 2010, 92 (11), 1501-8.
26. Natchus, M. G.; Bookland, R. G.; Laufersweiler, M. J.; Pikul, S.; Almstead, N. G.; De, B.; Janusz, M. J.; Hsieh, L. C.; Gu, F.; Pokross, M. E.; Patel, V. S.; Garver, S. M.; Peng, S. X.; Branch, T. M.; King, S. L.; Baker, T. R.; Foltz, D. J.; Mieling, G. E. Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. J. Med. Chem. 2001, 44 (7), 1060-71.
27. Holmes, I. P.; Gaines, S.; Watson, S. P.; Lorthioir, O.; Walker, A.; Baddeley, S. J.; Herbert, S.; Egan, D.; Convery, M. A.; Singh, O. M.; Gross, J. W.; Strelow, J. M.; Smith, R. H.; Amour, A. J.; Brown, D.; Martin, S. L. The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19 (19), 5760-3.
28. Janusz, M. J.; Hookfin, E. B.; Brown, K. K.; Hsieh, L. C.; Heitmeyer, S. A.; Taiwo, Y. O.; Natchus, M. G.; Pikul, S.; Almstead, N. G.; De, B.; Peng, S. X.; Baker, T. R.; Patel, V. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis. Inflammation Res. 2006, 55 (2), 60-5.
29. Monovich, L. G.; Tommasi, R. A.; Fujimoto, R. A.; Blancuzzi, V.; Clark, K.; Cornell, W. D.; Doti, R.; Doughty, J.; Fang, J.; Farley, D.; Fitt, J.; Ganu, V.; Goldberg, R.; Goldstein, R.; Lavoie, S.; Kulathila, R.; Macchia, W.; Parker, D. T.; Melton, R.; O'Byrne, E.; Pastor, G.; Pellas, T.; Quadros, E.; Reel, N.; Roland, D. M.; Sakane, Y.; Singh, H.; Skiles, J.; Somers, J.; Toscano, K.; Wigg, A.; Zhou, S.; Zhu, L.; Shieh, W. C.; Xue, S.; McQuire, L. W. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J. Med. Chem. 2009, 52 (11), 3523-38.
30. Cossi, M.; Rega, N.; Scalmani, G.; Barone, V. Energies, structures, and electronic properties of molecules in solution with the C-PCM solvation model. J. Comput. Chem. 2003, 24 (6), 669-81.
31. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46 (1-3), 3-26.